Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Public listing, Phase II cancer readouts in Cyteir’s sights as it banks $80M crossover round

By Paul Bonanos, Associate Editor
February 12, 2021 12:30 AM UTC

With early efficacy signals emerging from a dose-finding study, Cyteir will use its new $80 million series C crossover round to gain Phase II data in multiple cancers for its DNA damage repair (DDR) molecule targeting RAD51, the only one in its class to reach the clinic.

RA Capital led the round for Cyteir Therapeutics Inc., bringing the biotech’s total amount raised to more than $140 million since its 2016 series A. President and CEO Markus Renschler told BioCentury the company hopes to move forward with a public offering as soon as this year...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Cyteir Therapeutics Inc.

BCIQ Target Profiles

RAD51 homolog (RAD51)